Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1337-56. doi: 10.1517/17425255.2012.719874. Epub 2012 Aug 28.

An evaluation of sirolimus in renal transplantation.

Author information

  • 1Department of Nephrology, Charit√© Universit√§tsmedizin, Berlin, Germany. fabian.halleck@charite.de

Abstract

INTRODUCTION:

Sirolimus is a powerful antiproliferative immunosuppressive drug approved for the prevention of kidney allograft rejection. By its unique mechanism of action, sirolimus provides a multitude of clinical potential and has been used effectively in different drug combinations. Extensive experience has been gained regarding the best timing of its application, side effect profile and potential benefits and limitations compared with other immunosuppressive drugs.

AREAS COVERED:

The authors evaluate the recent experience with sirolimus in kidney transplantation. Pivotal randomized controlled trials were used to provide an overview with special attention to pharmacokinetic and dynamic aspects of sirolimus, its current clinical use as well as perspectives for its future role.

EXPERT OPINION:

Sirolimus enriches the possibilities of immunosuppressive therapies after renal transplantation. Beneficial effects toward kidney function by allowing CNI sparing, lower incidence of malignancies and less viral infections have been suggested. Sirolimus should be used cautiously in de novo patients for reasons of wound healing. An early conversion to a sirolimus-based CNI-free regimen has shown promising results, whereas late conversion is more challenging. Finally, sirolimus-associated side effects are causing tolerability concerns and frequent discontinuations. Future research should aim to better define the therapeutic window and those patients most likely to benefit.

PMID:
22928953
DOI:
10.1517/17425255.2012.719874
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center